Final report of survival and late toxicities in the Phase i study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer (JCOG0702)

Rikiya Onimaru, Hiroshi Onishi, Gakuto Ogawa, Masahiro Hiraoka, Satoshi Ishikura, Katsuyuki Karasawa, Yukinori Matsuo, Masaki Kokubo, Yoshiyuki Shioyama, Haruo Matsushita, Yoshinori Ito, Hiroki Shirato

Research output: Contribution to journalArticle

Abstract

Purpose A dose escalation study to determine the recommended dose with stereotactic body radiation therapy (SBRT) for peripheral T2N0M0 non-small cell carcinomas (JCOG0702) was conducted. The purpose of this paper is to report the survival and the late toxicities of JCOG0702. Materials and methods The continual reassessment method was used to determine the dose level that patients should be assigned to and to estimate the maximum tolerated dose. The starting dose was 40 Gy in four fractions at D 95 of PTV. Results Twenty-eight patients were enrolled. Ten patients were treated with 40 Gy at D 95 of PTV, four patients with 45 Gy, eight patients with 50 Gy, one patient with 55 Gy and five patients with 60 Gy. Ten patients were alive at the last follow-up. Overall survival (OS) for all patients was 67.9% (95% CI 47.3-81.8%) at 3 years and 40.8% (95% CI 22.4-58.5%) at 5 years. No Grade 3 or higher toxicity was observed after 181 days from the beginning of the SBRT. Compared to the toxicities up to 180 days, chest wall related toxicities were more frequent after 181 days. Conclusions The 5-year OS of 40.8% indicates the possibility that SBRT for peripheral T2N0M0 non-small cell lung cancer is superior to conventional radiotherapy. The effect of the SBRT dose escalation on OS is unclear and further studies are warranted.

Original languageEnglish
Pages (from-to)1076-1082
Number of pages7
JournalJapanese journal of clinical oncology
Volume48
Issue number12
DOIs
Publication statusPublished - Dec 1 2018

Fingerprint

Non-Small Cell Lung Carcinoma
Radiotherapy
Survival
Maximum Tolerated Dose
Thoracic Wall
Carcinoma

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Final report of survival and late toxicities in the Phase i study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer (JCOG0702). / Onimaru, Rikiya; Onishi, Hiroshi; Ogawa, Gakuto; Hiraoka, Masahiro; Ishikura, Satoshi; Karasawa, Katsuyuki; Matsuo, Yukinori; Kokubo, Masaki; Shioyama, Yoshiyuki; Matsushita, Haruo; Ito, Yoshinori; Shirato, Hiroki.

In: Japanese journal of clinical oncology, Vol. 48, No. 12, 01.12.2018, p. 1076-1082.

Research output: Contribution to journalArticle

Onimaru, R, Onishi, H, Ogawa, G, Hiraoka, M, Ishikura, S, Karasawa, K, Matsuo, Y, Kokubo, M, Shioyama, Y, Matsushita, H, Ito, Y & Shirato, H 2018, 'Final report of survival and late toxicities in the Phase i study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer (JCOG0702)', Japanese journal of clinical oncology, vol. 48, no. 12, pp. 1076-1082. https://doi.org/10.1093/jjco/hyy141
Onimaru, Rikiya ; Onishi, Hiroshi ; Ogawa, Gakuto ; Hiraoka, Masahiro ; Ishikura, Satoshi ; Karasawa, Katsuyuki ; Matsuo, Yukinori ; Kokubo, Masaki ; Shioyama, Yoshiyuki ; Matsushita, Haruo ; Ito, Yoshinori ; Shirato, Hiroki. / Final report of survival and late toxicities in the Phase i study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer (JCOG0702). In: Japanese journal of clinical oncology. 2018 ; Vol. 48, No. 12. pp. 1076-1082.
@article{ef21da61b5be40689a2ca7b68f24fa03,
title = "Final report of survival and late toxicities in the Phase i study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer (JCOG0702)",
abstract = "Purpose A dose escalation study to determine the recommended dose with stereotactic body radiation therapy (SBRT) for peripheral T2N0M0 non-small cell carcinomas (JCOG0702) was conducted. The purpose of this paper is to report the survival and the late toxicities of JCOG0702. Materials and methods The continual reassessment method was used to determine the dose level that patients should be assigned to and to estimate the maximum tolerated dose. The starting dose was 40 Gy in four fractions at D 95 of PTV. Results Twenty-eight patients were enrolled. Ten patients were treated with 40 Gy at D 95 of PTV, four patients with 45 Gy, eight patients with 50 Gy, one patient with 55 Gy and five patients with 60 Gy. Ten patients were alive at the last follow-up. Overall survival (OS) for all patients was 67.9{\%} (95{\%} CI 47.3-81.8{\%}) at 3 years and 40.8{\%} (95{\%} CI 22.4-58.5{\%}) at 5 years. No Grade 3 or higher toxicity was observed after 181 days from the beginning of the SBRT. Compared to the toxicities up to 180 days, chest wall related toxicities were more frequent after 181 days. Conclusions The 5-year OS of 40.8{\%} indicates the possibility that SBRT for peripheral T2N0M0 non-small cell lung cancer is superior to conventional radiotherapy. The effect of the SBRT dose escalation on OS is unclear and further studies are warranted.",
author = "Rikiya Onimaru and Hiroshi Onishi and Gakuto Ogawa and Masahiro Hiraoka and Satoshi Ishikura and Katsuyuki Karasawa and Yukinori Matsuo and Masaki Kokubo and Yoshiyuki Shioyama and Haruo Matsushita and Yoshinori Ito and Hiroki Shirato",
year = "2018",
month = "12",
day = "1",
doi = "10.1093/jjco/hyy141",
language = "English",
volume = "48",
pages = "1076--1082",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Final report of survival and late toxicities in the Phase i study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer (JCOG0702)

AU - Onimaru, Rikiya

AU - Onishi, Hiroshi

AU - Ogawa, Gakuto

AU - Hiraoka, Masahiro

AU - Ishikura, Satoshi

AU - Karasawa, Katsuyuki

AU - Matsuo, Yukinori

AU - Kokubo, Masaki

AU - Shioyama, Yoshiyuki

AU - Matsushita, Haruo

AU - Ito, Yoshinori

AU - Shirato, Hiroki

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Purpose A dose escalation study to determine the recommended dose with stereotactic body radiation therapy (SBRT) for peripheral T2N0M0 non-small cell carcinomas (JCOG0702) was conducted. The purpose of this paper is to report the survival and the late toxicities of JCOG0702. Materials and methods The continual reassessment method was used to determine the dose level that patients should be assigned to and to estimate the maximum tolerated dose. The starting dose was 40 Gy in four fractions at D 95 of PTV. Results Twenty-eight patients were enrolled. Ten patients were treated with 40 Gy at D 95 of PTV, four patients with 45 Gy, eight patients with 50 Gy, one patient with 55 Gy and five patients with 60 Gy. Ten patients were alive at the last follow-up. Overall survival (OS) for all patients was 67.9% (95% CI 47.3-81.8%) at 3 years and 40.8% (95% CI 22.4-58.5%) at 5 years. No Grade 3 or higher toxicity was observed after 181 days from the beginning of the SBRT. Compared to the toxicities up to 180 days, chest wall related toxicities were more frequent after 181 days. Conclusions The 5-year OS of 40.8% indicates the possibility that SBRT for peripheral T2N0M0 non-small cell lung cancer is superior to conventional radiotherapy. The effect of the SBRT dose escalation on OS is unclear and further studies are warranted.

AB - Purpose A dose escalation study to determine the recommended dose with stereotactic body radiation therapy (SBRT) for peripheral T2N0M0 non-small cell carcinomas (JCOG0702) was conducted. The purpose of this paper is to report the survival and the late toxicities of JCOG0702. Materials and methods The continual reassessment method was used to determine the dose level that patients should be assigned to and to estimate the maximum tolerated dose. The starting dose was 40 Gy in four fractions at D 95 of PTV. Results Twenty-eight patients were enrolled. Ten patients were treated with 40 Gy at D 95 of PTV, four patients with 45 Gy, eight patients with 50 Gy, one patient with 55 Gy and five patients with 60 Gy. Ten patients were alive at the last follow-up. Overall survival (OS) for all patients was 67.9% (95% CI 47.3-81.8%) at 3 years and 40.8% (95% CI 22.4-58.5%) at 5 years. No Grade 3 or higher toxicity was observed after 181 days from the beginning of the SBRT. Compared to the toxicities up to 180 days, chest wall related toxicities were more frequent after 181 days. Conclusions The 5-year OS of 40.8% indicates the possibility that SBRT for peripheral T2N0M0 non-small cell lung cancer is superior to conventional radiotherapy. The effect of the SBRT dose escalation on OS is unclear and further studies are warranted.

UR - http://www.scopus.com/inward/record.url?scp=85057171260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057171260&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyy141

DO - 10.1093/jjco/hyy141

M3 - Article

C2 - 30277519

AN - SCOPUS:85057171260

VL - 48

SP - 1076

EP - 1082

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 12

ER -